SCHEMBL5147530

SCHEMBL5147530

Cc1cccc(C(=S)SCC(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ HDAC8 Q9BY41 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ POLB P06746 3/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ FFAR1 O14842 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ GLA P06280 1/20 0.43
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9416233 0.83 TPMT (0.47) SMN1; SMN2HDAC8HDAC6KMT2ATP53
SCHEMBL162936 0.81 ALDH1A1 (0.52) SMN1; SMN2TDP1HPGDHDAC8HDAC6
SCHEMBL11852856 0.81 MEN1 (0.49) PARP1POLBMEN1KMT2AALDH1A1
SCHEMBL2705458 0.80 HDAC3 (0.51) SMN1; SMN2HDAC8HDAC6POLBMEN1
SCHEMBL4832150 0.79 ALDH1A1 (0.50) SMN1; SMN2TDP1HPGDHDAC8HDAC6
SCHEMBL11849614 0.77 CES2 (0.54) SMN1; SMN2HPGDPOLBRAB9AALDH1A1
SCHEMBL11842729 0.74 TP53 (0.46) SMN1; SMN2HDAC8HDAC6MEN1KMT2A
SCHEMBL11854782 0.74 MEN1 (0.53) SMN1; SMN2HPGDHDAC8HDAC6POLB
SCHEMBL18267481 0.73 FAAH (0.49) PARP1SMN1; SMN2TDP1HPGDHDAC8
SCHEMBL31309821 0.73 FAAH (0.49) PARP1SMN1; SMN2TDP1HPGDHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070112044-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-17 — — US disclosed
EP-1671957-A1 THIADIAZOLINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-06-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112044-A1 Thiadiazoline derivative TLK2, TLK1, BRWD1 PARP1 3025/4885SMN1; SMN2 3750/4885TDP1 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback